Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
68 hedge funds and large institutions have $53.1M invested in Novelion Therapeutics Inc. Common Shares in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 16 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
13% more capital invested
Capital invested by funds: $47.1M → $53.1M (+$5.97M)
17% less funds holding
Funds holding: 82 → 68 (-14)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
54% less call options, than puts
Call options by funds: $69K | Put options by funds: $149K
88% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.77M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$701K |
| 3 |
State Street
Boston,
Massachusetts
|
+$114K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$65.4K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$64.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$779K |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$269K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$163K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$138K |
| 5 |
VF
Virtu Financial
New York
|
-$138K |
NVLN Hedge Fund Activity: Q1 2018 in Review
68 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q1 2018, worth a combined $53.1M — up 13% from $47.1M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of NVLN and 2 opened new positions — a net loss of 14 holders — while 20 trimmed existing stakes and 15 added.
The largest buyer was Morgan Stanley, adding an estimated $1.77M. The largest seller was Dimensional Fund Advisors, cutting an estimated $779K.
- 68 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q1 2018, down from 82 in Q4 2017.
- Funds reported $53.1M of Novelion Therapeutics Inc. Common Shares stock for Q1 2018, up 13% quarter-over-quarter.
- 2 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q1 2018 and 16 closed out, a net change of -14 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q1 2018 was Morgan Stanley, an estimated $1.77M added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q1 2018 was Dimensional Fund Advisors, an estimated $779K sold.
Based on aggregated 13F filings for Q1 2018.